These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 33996902)

  • 1. LINC02257, an Enhancer RNA of Prognostic Value in Colon Adenocarcinoma, Correlates With Multi-Omics Immunotherapy-Related Analysis in 33 Cancers.
    Xiao J; Liu Y; Yi J; Liu X
    Front Mol Biosci; 2021; 8():646786. PubMed ID: 33996902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression characteristics of long non-coding RNA in colon adenocarcinoma and its potential value for judging the survival and prognosis of patients: bioinformatics analysis based on The Cancer Genome Atlas database.
    Li R; Gao X; Sun H; Sun L; Hu X
    J Gastrointest Oncol; 2022 Jun; 13(3):1178-1187. PubMed ID: 35837189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype.
    Qin N; Ma Z; Wang C; Zhang E; Li Y; Huang M; Chen C; Zhang C; Fan J; Gu Y; Xu X; Yang L; Wei X; Yin R; Jiang Y; Dai J; Jin G; Xu L; Hu Z; Shen H; Ma H
    Theranostics; 2020; 10(24):11264-11277. PubMed ID: 33042282
    [No Abstract]   [Full Text] [Related]  

  • 5. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
    Guo B; Wang Y; Liu W; Zhang S
    Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GAS1RR, an immune-related enhancer RNA, is related to biochemical recurrence-free survival in prostate cancer.
    Xiong Z; Ge Y; Xiao J; Wang Y; Li L; Ma S; Lan L; Liu B; Qin B; Luan Y; Yang C; Ye Z; Wang Z
    Exp Biol Med (Maywood); 2023 Jan; 248(1):1-13. PubMed ID: 36408742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of
    Zhang S; Xiong H; Yang J; Yuan X
    Front Mol Biosci; 2021; 8():792154. PubMed ID: 35155565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DCP1A is an unfavorable prognostic-related enhancer RNA in hepatocellular carcinoma.
    Wu H; Zhang J; Bai Y; Zhang S; Zhang Z; Tong W; Han P; Fu B; Zhang Y; Shen Z
    Aging (Albany NY); 2021 Oct; 13(19):23020-23035. PubMed ID: 34609335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive profiling of enhancer RNA in stage II/III colorectal cancer defines two prognostic subtypes with implications for immunotherapy.
    Bu X; Liu S; Zhang Z; Wu J; Pan S; Hu Y
    Clin Transl Oncol; 2024 Apr; 26(4):891-904. PubMed ID: 37697139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RecQ mediated genome instability 2 (
    Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
    Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Validation of an Immune-Related eRNA Prognostic Signature for Hepatocellular Carcinoma.
    Cai S; Hu X; Chen R; Zhang Y
    Front Genet; 2021; 12():657051. PubMed ID: 34178028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive prognostic and immune analysis of enhancer RNA identifies IGFBP7-AS1 as a novel prognostic biomarker in Uterine Corpus Endometrial Carcinoma.
    Liu J; Yin J; Wang Y; Cai L; Geng R; Du M; Zhong Z; Ni S; Huang X; Yu H; Bai J
    Biol Proced Online; 2022 Jul; 24(1):9. PubMed ID: 35836132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy.
    Jia Y; Guo B; Zhang W; Wang F; Zhang Y; Zhang Q; Li E
    Front Oncol; 2023; 13():1110207. PubMed ID: 37427102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic analysis of
    Jiang Y; Wang X; Li L; He J; Jin Q; Long D; Liu C; Zhou W; Liu K
    Front Genet; 2022; 13():926943. PubMed ID: 35991552
    [No Abstract]   [Full Text] [Related]  

  • 15. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA LINC02257: A Potential Biomarker for Diagnosis and Prognosis of Colorectal Cancer.
    Chen M; Li C; Luo Q; Tan A
    J Oncol; 2022; 2022():4330630. PubMed ID: 36124032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Analysis of
    Liu J; Zhu B; Chen J; Cao Y
    Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-Cancer Integrated Analysis of HSF2 Expression, Prognostic Value and Potential Implications for Cancer Immunity.
    Chen F; Fan Y; Liu X; Zhang J; Shang Y; Zhang B; Liu B; Hou J; Cao P; Tan K
    Front Mol Biosci; 2021; 8():789703. PubMed ID: 35087869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of ACBD3 as a new molecular biomarker in pan-cancers through bioinformatic analysis: a preclinical study.
    Ma X; Huang S; Shi H; Luo R; Luo B; Tan Z; Shi L; Zhang W; Yang W; Zhong X; Lü M; Chen X; Tang X
    Eur J Med Res; 2023 Dec; 28(1):590. PubMed ID: 38098097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of lncRNA-Associated ceRNA Network Reveals Potential lncRNA Biomarkers in Human Colon Adenocarcinoma.
    Zhang Z; Qian W; Wang S; Ji D; Wang Q; Li J; Peng W; Gu J; Hu T; Ji B; Zhang Y; Wang S; Sun Y
    Cell Physiol Biochem; 2018; 49(5):1778-1791. PubMed ID: 30231249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.